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Small-molecule fragments binding to biomacromolecules can be starting points for the
development of drugs, but are often difﬁcult to detect due to low afﬁnities. Here we present a
strategy that identiﬁes protein-binding fragments through their potential to induce the target-
guided formation of covalently bound, irreversible enzyme inhibitors. A protein-binding
nucleophile reacts reversibly with a bis-electrophilic warhead, thereby positioning the second
electrophile in close proximity of the active site of a viral protease, resulting in the covalent
de-activation of the enzyme. The concept is implemented for Coxsackie virus B3 3C protease,
a pharmacological target against enteroviral infections. Using an aldehyde-epoxide as
bis-electrophile, active fragment combinations are validated through measuring the protein
inactivation rate and by detecting covalent protein modiﬁcation in mass spectrometry. The
structure of one enzyme–inhibitor complex is determined by X-ray crystallography. The
presented warhead activation assay provides potent non-peptidic, broad-spectrum inhibitors
of enteroviral proteases.
DOI: 10.1038/ncomms12761 OPEN
1 Institute of Pharmacy, Medicinal Chemistry, Freie Universita¨t Berlin, Ko¨nigin-Luise-Strae 2þ4, 14195 Berlin, Germany. 2 Institute for Research in
Biomedicine, Parc Cientı´ﬁc de Barcelona, Baldiri Reixac 10-12, 08028 Barcelona, Spain. 3 Institut de Biologia Molecular de Barcelona (CSIC), Parc Cientı´ﬁc de
Barcelona, Baldiri Reixac 10-12, 08028 Barcelona, Spain. 4 Institute of Biochemistry, University of Lu¨beck, Ratzeburger Allee 160, 23562 Lu¨beck, Germany.
5 German Center for Infection Research (DZIF), Hamburg–Lu¨beck–Borstel Site, University of Lu¨beck, 23562 Lu¨beck, Germany. Correspondence and requests
for materials should be addressed to J.R. (email: joerg.rademann@fu-berlin.de).
NATURE COMMUNICATIONS | 7:12761 | DOI: 10.1038/ncomms12761 | www.nature.com/naturecommunications 1
A
t present, bioactive protein ligands are discovered mostly
by the screening of chemical libraries employing a suitable
bioassay as a test system. In contrast to classical screening,
the templated assembly of protein ligands during the bioassay
could be a tantalizing alternative having the potential to identify
non-canonical protein ligands with improved potency,
ligand efﬁciency and selectivity, while employing reduced human,
ecological and ﬁnancial resources1–6. Protein-templated reactions
are driven by the (kinetic) enhancement of the ligand-forming
reaction or by the thermodynamic stabilization of the protein-
binding ligation product, or by a combination of both. In any of
the cases, however, the enhanced binding of a fragment ligation
product will be accompanied by a shift of the ligation equilibrium
and by the templated and enhanced formation of the bound
ligation product. Enhanced binding of the fragment ligation
product corresponds to over-additivity of fragment binding,
which can be detected sensitively in biochemical and biophysical
experiments.
Both reversible2,7–11 and irreversible12–20 reactions have been
employed for the formation of protein ligands through covalent
templated assembly. In this contribution, we investigate the
combination of a reversible templated reaction and an irreversible
templated reaction, which will enable the protein-guided
assembly of protein ligands and their subsequent reaction as
irreversible enzyme inhibitors. The described reaction sequence
enables the testing of combinations of nucleophilic fragments and
electrophilic warheads in a biochemical assay and inhibitory
fragment combinations detected in this ‘warhead activation assay’
are used as blueprints for the construction of potent irreversible
enzyme inhibitors. The described warhead activation assay is
rationalized by structural and kinetic analysis of the formed
fragment ligation products and is supported by molecular
modelling of the putative intermediary fragment–protein
complexes. Site-speciﬁc binding of several inhibitors is veriﬁed
by protein mass spectrometry and the structure of one enzyme–
inhibitor complex is determined by protein crystallography. The
most potent inhibitors possess broadband sub-micromolar
activity towards a panel of seven entero- and rhinoviral 3C
proteases indicating the feasibility of the fragment ligation
approach described.
Results
Concept of the fragment-warhead activation assay. The envi-
saged fragment-warhead activation assay is based on the idea that
a templated ligation reaction of a protein-binding fragment with
an electrophilic warhead should lead to the accelerated irrever-
sible inhibition of the protein, if a reactive protein nucleophile is
present (Fig. 1). In this concept, a nucleophilic small-molecule
fragment binds to a binding site of a protein (Fig. 1a, step 1). The
protein-binding fragment undergoes a reversible ligation reaction
with a bis-electrophilic protein-reactive group (warhead)21,22
(step 2). The ligation reaction thereby positions the second
reactive electrophilic functionality of the warhead at the active site
of the protein inducing an irreversible, covalent reaction of the
active-site nucleophile with the warhead (step 3) resulting in the
irreversible deactivation of the protein. The described reaction
sequence enables the testing of combinations of nucleophilic
fragments and electrophilic warheads in a biochemical assay and
inhibitory fragment combinations detected in this ‘warhead
activation assay’ are blueprints for the construction of potent
irreversible enzyme inhibitors.
Selection of the protein target. As a protein target, the 3C
protease of Coxsackie virus B3 (CVB3 3C protease) was selec-
ted23,24. Coxsackie viruses are members of the large genus of
enteroviruses, representing uncoated positive-strand RNA viruses
of the picornavirus family and causing numerous human diseases
including meningitis, myocarditis and diarrhea25–28. The genus
Enterovirus comprises numerous human pathogens, including
rhinoviruses, polioviruses, echoviruses and other human-
infecting viruses like EV-A71 and EV-B93 (refs 26,29,30).
Coxsackie virus 3C protease, like other enteroviral proteases, is
a cysteine protease with a characteristic speciﬁcity for glutamine
in the P1 position of its substrates (Fig. 1b). Thus, for this target,
fragments binding to the S1 pocket are biomimetics of the
glutamine side chain, while the active-site nucleophile is the
thiolate of cysteine 147 (Cys-147).
Development of warhead activation assay. Several bis-electro-
philes were considered as warheads for the warhead activation
assay. Enantiomerically pure ethyl (2S,3S)-epoxy-4-oxo-butano-
ate 1 was selected and prepared from commercially available ethyl
4-oxo-but-(2E)-enoate31. This warhead contains both an
aldehyde and an epoxide functionality as electrophilic reaction
sites for the ligation with a protein-binding, nucleophilic
fragment and the irreversible alkylation reaction with the
active-site cysteine of the protease. The 2,3-trans-epoxysuccinyl
structure is derived from the natural cysteine protease inhibitor
E-64 and has been recognized as a privileged reactive warhead































Figure 1 | Concept of the fragment-warhead activation assay. (a) Protein-
templated, covalent assembly of an irreversible inhibitor of a cysteine
protease: reversible binding of a nucleophilic fragment (Nu¼ nucleophile)
to the S1-site (step 1) positions the bis-electrophilic warhead 1 in a
templated dynamic reaction at the active site of the protein (step 2),
leading to irreversible inhibition of the protein (step 3). In the case that Nu
is an amine nucleophile (Nu¼NHR), an imine intermediate instead of the
depicted hemiaminal may be formed. (b) The active site of an enterovirus
3C protease with a bound peptide substrate containing a glutamine residue
(Gln, Q) in P1 position occupying the S1 pocket of the enzyme.
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alone was investigated as an inhibitor of the 3C protease of
Coxsackie virus B3 (Fig. 2).
Employing an enzymatic protease assay with a substrate
containing a ﬂuorescence-resonance energy transfer (FRET)
pair, fragment 1 was identiﬁed as a weak, irreversible inhibitor
of the CVB3 3C protease with a relative inactivation rate
(kinact/KI-value) of 2.4±0.1M 1 s 1. This inactivation rate
corresponded to an apparent half-maximal inhibitory concentra-
tion (IC50) value of441mM after 10min (Fig. 2b, Table 1). The
covalent mode of action was conﬁrmed by electrospray ionization
high-resolution ion mobility spectrometry-mass spectrometry
(ESI-MS) measurements. Incubation of the protease with
warhead 1 shifted the main deconvoluted mass peak of the
protein from 21,471.5 to 21,588.5Da and the observed protein
mass difference of 117Da corresponded well with the molecular
weight of bis-electrophile 1 after hydrolysis of the ethyl ester.
Next, a fragment ligation assay was conducted to identify
nucleophilic fragments inducing the deactivation of the protein
through a ligation reaction with fragment 1. For this purpose, a
concentration of fragment 1 was determined, which decreased the
activity of the protease by B10% over a time period of 10min.
This level of inhibition was used to ascertain the maximal
sensitivity of the assay. A small library of 850 primary amine
fragments, composed by applying a substructure analysis of the
World Drug Index35, was screened in the fragment ligation assay.
Fragment 2, 5-amino-1-cycloheptyl-1,2-dihydropyrazol-3-one
(Fig. 3a, Supplementary Table 1), displayed the strongest over-
additive effect of inhibition of protease activity. While fragments
1 or 2 alone reduced the enzyme’s activity by no more than 10%,
the protease was inhibited completely by a combination of 1 and
2 at the same concentrations (Fig. 3b). Incubation of the protease
with mixtures of 1 (1.2 equiv.) and 2 (1 equiv.) led to a
concentration-dependent deactivation of the enzyme with an
apparent IC50 value of ca. 200 mM and a kinact/KI of
8.3±0.6M 1 s 1 (Supplementary Fig. 1). Deconvolution of
the ESI-MS of the protease after ligation with a mixture of both
fragments 1 and 2 showed the modiﬁcation of the protein mass
by addition of both fragments (144þ 195¼ 339Da) as the major
mass peak (100% intensity, see Fig. 3c). For comparison, the mass
peak for the remaining unmodiﬁed protein displayed only 12%
intensity and that of the protein coupled to the bis-electrophile 1
alone ca. 8%, supporting the assumption that the protein
modiﬁcation was strongly ampliﬁed by the presence of
fragment 2. Incubation of the mutated protease C147A (ref. 36)
did not display any modiﬁcation in MS, indicating a selective
alkylation of the active site.





































































Figure 2 | Development of the bis-electrophilic warhead 1. (a) Deactivation of Coxsackie virus 3C protease by reaction with bis-electrophilic warhead 1.
Reaction scheme. (b) Inhibition of the protease in the FRET-based enzyme activity assay at various concentrations of 1. (c) Deconvoluted ESI-mass
spectrum of the reaction of the protease with 1. The mass of the unmodiﬁed protein, 21,471.5Da, is shifted to a main peak at 21,588.5Da, corresponding
to the mass of the protein þ 1 after cleavage of the ethyl ester. The peak at 21,755.5 corresponds to the protein mass þ 1 þTris (buffer)–water.
(d) Deactivation of the protease is quantiﬁed as relative inhibition, the observed deactivation rate, kobs, plotted against inhibitor concentration. The slope of
the linear regression curve of the kobs values plotted against the corresponding concentration value yields the kinact/KI-value for compound 1 and equals
2.4±0.1M 1 s 1.
Table 1 | Synthesized inhibitors 1–21 and their kinact/KI or
IC50 values with Coxsackie 3B virus 3C protease.
Compound number kinact/KI(M
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The ligation reaction of fragments 1 and 2 was analysed by
HPLC/MS with and without the protein target present
(Supplementary Fig. 2). Several different addition products of 1
and 2 were formed according to mass analysis and retention
times and two of these products had the additive mass of both
fragments, which had been observed in the deconvoluted MS of
the protein sample reacted with both fragments. This formation
of several different addition products of 1 and 2 is in agreement
with the reported reactivity of 5-amino-1,2-dihydropyrazol-3-
ones, which were found to react with electrophiles at both the
exocyclic amino group, the carbonyl oxygen and in the carbon-4
position37,38. The product ratio varied strongly depending on the
solvent and presence/absence of the protein target. Isolation of
the formed ligation products by preparative column
chromatography furnished again mixtures of compounds,
indicating that they were formed reversibly in an equilibrium
reaction. To evaluate the potential of the various ligation products
as inhibitors, possible fragment combinations were generated
in silico and docked39 into the active site. Docking poses were
selected according to their ability to bind and react in a similar
manner as observed in PDB entry 3ZZA representing the crystal
structure of CV3B 3C protease. In particular, two criteria were
applied: (i) the hydrogen-bonding pattern between the lactam
moiety of the co-crystallized ligand, and His-161 and Thr-142 in
the S1 pocket had to be fulﬁlled by the docked poses for a
plausible position in the binding site and (ii) the distance of
cysteine sulfur and the potentially covalently binding electrophile
of the ligation product had to be in a reasonable range for
subsequent covalent binding (Supplementary Table 2). Docking
of fragment 2 suggested that 2 can bind to the S1 pocket of the
protease occupying the position of the primary amide of the
native glutamine residue (Fig. 3d). Sampling the various reaction
paths of the electrophile 1 with the nucleophilic positions of
fragment 2 supported the best ﬁt for a nucleophilic attack by the
carbon-4 ring position (Fig. 3e). According to our docking
experiments, the putative reaction product, a secondary alcohol,
can be positioned in the active site of the protein and can be
attacked by Cys-147 resulting in the opening of the epoxide ring
and the formation of the covalent protein modiﬁcation (Fig. 3f).
Fragment-based inhibitor design. Based on the observation that
fragment 2 is a potent activator of bis-electrophile 1 inducing the
assembly of an irreversible protease inhibitor, a set of fragment
combinations was designed, varying the chemical nature and the
attachment of the protein-reactive electrophile (Fig. 4, Table 1,
Supplementary Table 1). Trans-epoxide 3 was a moderately active
irreversible inhibitor of the protease (kinact/KI¼ 3.7M 1 s 1),
while trans-epoxide 4 was a reversible inhibitor of the enzyme.
Cis-epoxide 5 was inactive as expected, so was the naphtyl-
1-methyl amide 6, which was designed according to a recent
report40. Increased reactivity with the protease was observed,
when alternative electrophiles were linked to the primary
fragment 2. While the acrylic ester derivative 7 was only a
weak irreversible inhibitor with kinact/KI to 0.4M 1 s 1, the
ethyl fumaroyl electrophile in 8, containing also a trans-oleﬁne,
raised the relative inactivation rate to 132M 1 s 1, more than
60-fold than the initial electrophile 1. The same electrophile, an
N-fumaroyl ester, was inactive in the 5-amino position as shown
by compound 9. Converting the stereochemistry at the double
bond of 9 furnished the N-maleoyl ester 12 displaying an
impressive inactivation rate of 606M 1 s 1. To assure that the
inhibition of 12 was effected by the amino-pyrazolone fragment,
the unsubstituted maleoyl amide ester 13 was prepared and found
to be only moderately active (34M 1 s 1).
Transformation of the ethyl ester 12 to the ethyl amide 14
reduced the inactivation rate by 10-fold (63M 1 s 1). The
maleoyl-diamide 15 was fully inactive. Further enhancement of
the inactivation was accomplished by trans-vinyl sulfone 20
displaying the maximal inactivation rate of 1,008M 1 s 1.
m/z












































Figure 3 | Results of screening a fragment library using the warhead activation assay. (a) Molecular modelling of the reversible binding of fragment 2 to
the S1 pocket of Coxsackie virus protease, the reversible ligation of warhead 1, and the irreversible modiﬁcation of Cys-147. The most important interactions
are shown as red dotted lines. (b) Over-additive inhibition of Coxsackie virus protease by combination of warhead 1 and fragment 2. 1 and 2 alone are
virtually inactive. (c) Deconvoluted ESI-mass spectrum of the 3C protease after incubation with warhead 1 and fragment 2. Main mass signal at 21,811.5Da
corresponds to the mass of the protein complex þ 1 þ2. (d–f) Three-dimensional illustrations of fragment binding to the S1 pocket of CV3B 3C protease
obtained by docking experiments. (d) Initial non-covalent binding of fragment. (e) Non-covalent binding of the fragment ligation product. (f) Covalent
binding of ligation product after epoxide opening.
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Replacement of the 1-N substituent cyclohexyl in the most active
inhibitors 8, 12 and 20 by hydrogen, N-isopropyl, N-phenyl or N-
hept-4-yl yielded the weaker inhibitors 18, 21, 10 and 17,
respectively.
Broad-spectrum inhibitors of viral 3C proteases. Three of
the most potent inhibitors of CBV 3C protease derived of the
S1-binding amino-pyrazolone fragment 2, maleoyl ester 12,
maleoyl-diamide 14 and vinyl sulfone 20 were tested towards a
panel of six additional rhinoviral and enteroviral 3C proteases,
equine rhinitis B virus (ERBV-1), human rhinovirus A49
(HRV-A49), human enterovirus D68 (EV-D68), Aichi virus 1
(AiV-1), porcine sapelovirus 1 (PSV-1) and human enterovirus
B93 (EV-B93) at protein inhibitor stoichiometries of 1:1 and 1:3
(Fig. 5). Inhibitors 12 and 20 under these conditions strongly
reduced the activity of all six proteases investigated, with 20 being
generally more potent than 12. All compounds, 12, 14 and 20,
showed the highest inhibition for EV-B93 and both 14 and 20
fully inhibited the enzyme even at one inhibitor equivalent. For
12 and 14, the inhibitory activity decreased for EV-B934PSV-
14ERBV-14AiV-14EV-D684HRV-A49.
IC50 values of the most active compounds were determined by
incubation of a ﬁxed enzyme concentration for 3 h with different
concentrations of inhibitors 14 and 20 (Table 2) and the most
potent inhibitor, compound 20, showed sub-micromolar inhibi-
tion for all tested viral proteases, with strongest inhibition for EV-
B93, followed by PSV-1, AiV-1, ERBV-1, HRV-A49, and ﬁnally
HEV-D68, with ERBV-1 being the only protease tested where 12
is more active than 20.
Finally, the selectivity of the representative inhibitors 14 and 20
was validated using four proteases possessing nucleophilic amino-
acid residue in the active site, namely the serine proteases trypsin,
chymotrypsin, and factor Xa and the cysteine protease caspase-3.




























































































































































































































Figure 5 | Inhibition of 6 different 3C proteases by compounds 12, 14 and
20. 3C proteases from equine rhinitis B virus (ERBV-1), human rhinovirus
A49 (HRV-A49), human enterovirus D68 (EV-D68), Aichi virus 1 (AiV-1),
porcine savelovirus 1 (PSV-1) and human enterovirus B93 (EV-B93) were
tested at different protease to inhibitor ratios.
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for arginine/lysine (trypsin, factor Xa), hydrophobic residues
(chymotrypsin) and aspartate (caspase-3). Compound 14 was
inactive towards all four proteases (IC504500mM); compound 20
was inactive towards the three serine proteases (IC504500mM)
and revealed very low inhibition of the cysteine protease caspase-
3 (IC504300mM) (Supplementary Table 3).
Structure of EV-B93 3C protease with inhibitor 14. Com-
pounds 12, 14 and 20 were incubated with EV-B93 3C protease.
The enzyme was repuriﬁed by size-exclusion chromatography
and subjected to crystallization trials. The protein complex with
14 gave well-diffracting crystals, which showed the presence of
additional electron density in the active site corresponding to the
molecular structure of the inhibitor. The high-resolution struc-
ture (PDB: 5IYT, 1.73Å) of the protease–inhibitor complex
revealed several additional aspects of the inhibition of the
protease with compound 14.
As described by our docking studies, exclusively the electro-
philic C-2 of 14 was attacked and covalently linked to the
nucleophilic Cys-147, forming a stable tetrahedral Michael
addition product (Fig. 6a–c). As a result, 14 is inserted between
the solvent-exposed b-strand E2 and the loop formed by Thr-142,
Arg-143, and Ala-144 and occupies the S1 and S10 sub-pockets of
the protein. Other than the reference inhibitor AG-7404 (Fig. 6d),
which is attacked at C-3 (see asterisk), the C-1 carbonyl oxygen of
the ethyl amide in 14 is oriented towards the oxyanion hole and
forms a hydrogen-bonding network with the backbone amides of
Cys-147, Gln-146 and Gly-145. The N-ethyl group points into the
S10-pocket. The pyrazolone ring of 14 is sandwiched in the S1
pocket by pp interactions with the peptide bonds between
Arg-143—Ala-144 on one side and the Gly-164—Asn-165 on the
other side. The pyrazol-5-amide NH interacts with Arg-143,
Gly-164, and a water molecule that mediates a hydrogen bond to
His-161.
In addition, plausible hydrogen bonds were identiﬁed between
the pyrazolone ring, and both Gly-164 and Thr-142 as well as to a
water molecule that supports the interaction with Ala-144. The
cycloheptane shows only weak electron density indicating the
ﬂexible orientation of this part of the molecule at the protein
surface, a van der Waals interaction is observed between the ring
C4 atom and the side-chain Cb atom of Ala-144. In summary, the
crystal structure shows that the binding of compound 14 is
distinct from that of the established inhibitors such as AG-7404
in several aspects that contribute to an understanding of the
observed inhibitory activities. The modiﬁed warhead structure
Table 2 | IC50 values of inhibitors 14 and 20 towards seven viral 3C proteases.
Inhibitor ERBV-1 HRV-A49 HEV-D68 AiV-1 PSV-1 EV-B93 CBV
14 410mM 4420mM 4420mM 9mM 8mM 4mM 13mM






































Figure 6 | Crystal structure of inhibitor 14 with 3C protease of EV-B93 (PDB: 5IYT). (a) Reﬁned structure of the enzyme–inhibitor complex with 14
represented as sticks, carbon atoms in yellow. (b) Close-up of the substrate-binding site with bound 14 and AG-7404 (carbon atoms in green); sub-
pockets S1’, S1, S2 and S4 are annotated. Water molecules are represented as red spheres. (c) Binding modes of 14; EV-B93 3C amino-acid residues in close
proximity to 14 are labelled in the S1 and S1’ sub-pockets. The arrows represent the H-bonds between 14, water molecules crucial for inhibitor binding and
the protein. (d) Structures of inhibitors 14 and AG-7404 with the carbon covalently attacked by the sulfur nucleophile of the protease being highlighted by
an asterisk.
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seems to favour binding through an additional interaction with
the oxyanion hole and with the p-stacking of the pyrazolone. For
comparison compounds 12 and 20 were docked to the enzyme
and similar binding poses as in the crystal structure were obtained
(Supplementary Fig. 3).
Discussion
In this contribution, a method for the covalent, protein-templated
assembly of irreversible enzyme inhibitors is described and
implemented. The approach combines a reversible, dynamic
fragment ligation reaction with an irreversible covalent modiﬁca-
tion and inhibition of the target enzyme, Coxsackie virus B3 3C
protease. Starting point for the discovery of protein-binding
fragments was the bis-electrophilic warhead, epoxy-aldehyde 1,
which combines an electrophilic motif for irreversible inhibition
of cysteine proteases, the epoxide, with an aldehyde electrophile
for the dynamic ligation of nucleophilic fragments. Warhead 1
alone was only a weak inhibitor of CVB3 3C protease but enabled
the sensitive detection of a protein-binding fragment 2, a
pyrazolone, from a collection of nucleophilic fragments. Using
a FRET-based assay for protease activity, it could be demon-
strated that the reversibly formed ligation product of 1 and 2 led
to a 3.5-fold enhancement of the protein inactivation rate from
2.4 to 8.3M 1 s 1 resulting in the strongly over-additive
inhibition of the protease from 10 to 100% inhibition. The
templating effect of the protease was conﬁrmed by mass
spectrometry showing that inhibition of the protease activity
corresponded with shifting the equilibrium to the protein–
fragment-warhead complex and thus resulted in the covalent
modiﬁcation of the enzyme’s active site.
To develop more potent irreversible inhibitors of enteroviral
proteases, the validated hit fragment 2 obtained from the
inhibitor assembly assay was modiﬁed varying the electrophilic
warhead and its attachment to the S1-binding fragment. In this
endeavor, starting from an irreversible inhibitor with a relative
inactivation rate of 2.4M 1 s 1 for warhead 1, the combination
with S1-binding fragment 2 furnished potent irreversible
inhibitors for several Michael acceptors, most pronounced
for (E)-oleﬁnes like compound 8 (kinact/KI¼ 131.7M 1 s 1),
(Z)-oleﬁnes like compounds 12 and 14 (kinact/KI¼ 606.4 and
63.1M 1 s 1, respectively), and vinyl sulfones such as inhibitor
20 (kinact/KI¼ 1,007M 1 s 1).
Testing of the activity of the inhibitors 12, 14 and 20 against a
panel of six enteroviral proteases indicated that the most potent
inhibitors were broad-spectrum inhibitors of this family of
genetically related proteases; the most potent inhibitor 20 showed
half-maximal inhibitory activities at sub-micromolar concentra-
tions. Broad-spectrum inhibition of enteroviral proteases is highly
desirable for the development of drugs that should be applicable
in the case of numerous diseases caused by already known and
newly emerging enteroviruses.
Compounds 14 and 20 were also validated as inhibitors against
a set of four human proteases possessing a nucleophilic active-site
residue and were found inactive at concentrations of 100 mM.
These results indicate the selectivity of the inhibitors for
enteroviral proteases and conﬁrm the selective recognition of
the pyrazolone fragment in 14 and 20 by the S1-binding pocket of
enteroviral proteases, which selectively bind substrates containing
glutamine in P1. On the contrary, the tested serine/cysteine
proteases with S1-preference for arginine, as trypsin and factor
Xa, or for hydrophobic residues, as chymotrypsin, or for
aspartate, as caspase-3, did not bind inhibitors 14 and 20.
A crystal structure of the complex of EV-B93 3C protease with
compound 14 (PDB: 5IYT) ﬁnally conﬁrmed the initial
hypothesis that protein-binding fragments can be detected in a
site-speciﬁc manner via a templated ligation reaction with a
bis-electrophilic probe to furnish irreversible protease inhibitors.
Beyond the discovery of a class of irreversible, non-peptidic
inhibitors of enteroviral 3C proteases, this work has demonstrated
a potentially broader concept, how to identify reversibly formed,
bioactive fragment ligation products through coupling a dynamic
ligation reaction with an irreversible alkylation of the protein
target. In this concept, the protein template binding the initial
fragment shifts the ligation equilibrium and thereby induces the
protein modiﬁcation reaction. The method should be principally
applicable to other protein surfaces provided that the following
three conditions are met: a protein-binding nucleophilic frag-
ment, a bis-electrophile (warhead) that is able to bind to the
fragment nucleophile and a nucleophilic protein site that enables
the irreversible reaction with the bis-electrophile. Consequently,
success of the method with alternative protein targets can be
expected, if the bound fragment, the bis-electrophile, and the
nucleophilic protein site ﬁt spatially and in terms of their
chemical reactivity. It should also be noted, however, as
demonstrated in the presented work that initially detected
fragment-warhead combinations can be optimized further by
chemical modiﬁcation.
Methods
Protocols and reaction schemes for the chemical synthesis of compounds 1–21 as
well as other methodological information are reported in the Supplementary
Methods. For characterization and purity of the compounds in this article, see
Supplementary Figs 4–29. Identity and purity (495%) of all compounds were
determined by chromatography (silica or RP-18 HPLC), by fully assigned 1H- and
13C-NMR spectra and by high-resolution mass spectra. Protein assays were
performed with recombinantly expressed viral proteases. Negative control sets
(omission of protease), positive control sets (omission of inhibitor), and controls
for autoﬂuorescence of substrate or inhibitor were carried out and did not interfere
with the assay readout unless noted otherwise. KM- and vmax-values were
determined by double reciprocal plotting of the measured activity against the
concentration of substrate (Lineweaver–Burk). Enzyme kinetics were determined
with a Fluorimeter SAFIRE II from Tecan (Crailsheim, Germany). Assays were
conducted on polystyrene 384-microtiter plates from Corning (model 3,544).
Mass spectrometry of protein-inhibitor samples. High-resolution mass spectra
were recorded on a Synapt G2-S HDMS by Waters Co. (Milford, UK) equipped
with an Acquity UPLC and a Phenomenex Jupiter C-18 column (3 250mm,
5 mm, 300Å). The ionization and transfer parameters of the MS system have been
optimized for a standard sample (insulin) and were applied without modiﬁcation.
Deconvolution of measurement results was performed by the MaxEnt1 method of
the MassLynx software by Waters Co. The most important source parameters are:
capillary voltage: 3.3 kV, sampling cone: 40 V, source offset: 60V, source tem-
perature: 100 C, desolvation temperature: 250 C, desolvation gas ﬂow: 600 l h 1.
Chromatographic conditions: start 95% solvent A, within 35min linear gradient to
1% solvent A, 5min 1% solvent A, within 4min back to 95% solvent A. Solvent
composition: A—water, 0.1% formic acid; B—acetonitrile, 0.1% formic acid. Flow
rate: 0.5mlmin 1. For mass spectra of protease–inhibitor complexes in this
article, see Supplementary Figs 30–35.
Recombinant protein production and puriﬁcation. The enzymatically active 3C
protease of Coxsackie virus B3 consisting of 183 amino-acid residues and carrying
an additional C-terminal sixfold histidine tag was expressed from the plasmid pET-
23a(þ ) (Novagen). The cDNA of the 3C protease corresponds to GenBank
accession no. M88483.1. Protein production and puriﬁcation followed standard
conditions. Brieﬂy, a clone of BL21(DE3) E. coli cells transfected with the coding
plasmid was grown in LB medium in the presence of ampicillin (100 mgml 1)
until OD600nm reached 0.6. Expression was induced by adding IPTG to a ﬁnal
concentration of 1mM and further incubation was carried out for 4 h at 37 C.
Cells were harvested by centrifugation and lysed by ultrasonication in 25mM
Tris-HCl pH 7.5/50mM NaCl/1% (v/v) Triton X-100/10% (v/v) glycerol/2mM
DTT. The extract was clariﬁed by centrifugation and separated on NiNTA agarose
(Qiagen) in 50mM Tris-HCl pH 8.0/500mM NaCl applying a step gradient of 50
to 500mM imidazole. Eluates of highest volume activity were pooled and further
separated on a preparative Superdex 75 column (GE Healthcare) equilibrated in
25mM HEPES-NaOH pH 7.5/50mM NaCl. The ﬁnal pool of recombinant pro-
tease was adjusted to 20% (v/v) glycerol and frozen in aliquots at  80 C until use.
EV-B93 3C protease expression and puriﬁcation was conducted as previously
described41. Other proteases were obtained from the European Virus Archive
(http://www.european-virus-archive.com/).
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Assay for template-assisted assembly of protease inhibitors. The activity of
the protease was measured by hydrolysis of the FRET-substrate N-Dabcyl-
KTLEALFQkGPPVYE(Edans)-NH2. The peptide was purchased from Biosyntan
(Berlin, Germany). Samples were irradiated with light with a wavelength of 355 nm
and the emitted light at 538 nm was measured in relative ﬂuorescence units (RFUs).
An amount of 100 pmol of cleaved substrate equals 5,000 RFU.
Assay samples contained 10 ml of a 100mM HEPES-NaOH buffer solution pH
7.5/1mM EDTA, 10ml enzyme solution (2 mM CVB3 3CPro), 10 ml of 10mM
substrate solution (both dissolved in the above buffer) and 1 ml Inhibitor and/or
fragment dissolved in DMSO. For assay results of a dilution series of a mixture of 1
and 2 and comparison of reaction products in dependence of the assay solvent, see
Supplementary Figs 1 and 2.
The screening procedure consisted of the following steps: 10 ml 100mM
HEPES-NaOH buffer solution pH 7.5/1mM EDTA was placed in a cavity
of the 384-well plate (polystyrene, Corning 3544). Then 10 ml of enzyme solution
(40 mM CVB3 3C protease in 100mM HEPES-NaOH buffer solution, pH 7.5/1mM
EDTA) was added and the plate was shaken for 2min at 1,400 r.p.m. Afterwards,
0.5 ml of a DMSO solution of the electrophilic probe and 0.5 ml of a DMSO solution
of the nucleophile was added, followed by 10 ml of substrate solution (10mM in
100mM HEPES-NaOH buffer solution, pH 7.5/1mM EDTA). The plate was
shaken again for 2min at 1,400 r.p.m. and the generated ﬂuorescence signal was
measured with a Saﬁre II Fluorimeter from Tecan. The electrophilic probe 1 was
used at a concentration of 400mM for the screening, which lowered the protease
activity by 10–20%. Eight-hundred ﬁfty primary amines were tested at a
concentration of 320 mM and fragment 2 ampliﬁed the inhibitory activity of 1 most
potently. Positive control samples contained only DMSO instead of the probe or
the nucleophile. Negative control samples contained no active enzyme. An
interfering ﬂuorescent effect has not been observed.
When determining the inhibitory parameters of an inhibitor, the assay set-up
was as mentioned but 1 ml DMSO solution of inhibitor was used instead of probe or
nucleophile. Different concentrations of inhibitor were tested at least as duplicates
and the pseudo-ﬁrst-order association kinetics (kobs) were determined using
GraphPad Prism. The slope of a plot of the different kobs values against the
inhibitor concentration yielded kinact/KI.
In vitro proteolytic activity assay. A volume of 100 ml of reaction mixture
containing 1.9 mM 3C protease, 25 mM substrate peptide, 5% DMSO, buffer
(30mM Tris pH 8.0, and 50mM NaCl or 50mM HEPES pH 7.4 and 50mM NaCl)
and (optionally) different concentrations of inhibitor was incubated in 37 C
during 3 h. The reaction was quenched by addition of 0.5% (ﬁnal concentration)
TFA. Samples were analysed by HPLC on SOURCE 15RPC ST 4.6/100 column
using: 2–90% linear gradient of ACN in 0.1% TFA. The 3C protease activity in the
absence of inhibitor was deﬁned as 100%. The following peptides (GL Biochem,
Shanghai, China) were dissolved in DMSO at a concentration of 5mM and used
for testing 3C proteases activity (Table 3).
Reaction of EV-B93 3C protease with inhibitor 14. The EV-B93 3C protease was
mixed with a 12-fold molar excess of the inhibitor and incubated overnight at
30 C. The complex was puriﬁed by gel ﬁltration (Superdex 75 10/300, GE
Healthcare) in 10mM Tris, pH 8.0, 200mM NaCl, 2mM DTT. The collected
fractions were concentrated to 2.3mgml 1 for crystallization.
Crystallization and structure determination. Crystals were grown by the sitting-
drop vapour diffusion method at 20 C by mixing equal volumes of protein
solution and reservoir solution containing 25% polyethylene glycol 3,350, 0.2M
ammonium acetate, and 0.1M Bis-Tris, pH 6.5. Crystals were transferred to
cryoprotectant solution comprising mother liquor and 25% glycerol for a few
seconds and ﬂash-cooled in liquid nitrogen. X-ray diffraction data were collected at
beamline XALOC at the ALBA synchrotron (Cerdanyola del Valle`s, Barcelona)
(Table 4). Diffraction data were indexed and integrated using XDS42, and scaled
and merged with SCALA43. Structure elucidation and reﬁnement were carried out
using the CCP4 suite of programs44. The initial phases were obtained by molecular
replacement using PHASER45 with the previously solved EV-B93 3C structure as
search model (PDB code: 3Q3X)41. REFMAC46 was employed for structure
reﬁnement and Coot47 for interpretation of electron density and model building.
Geometry restraint information for 14 was generated with SKETCHER within
CCP4. For a stereo image of the electron density map of the binding site of the
protease–inhibitor complex see Supplementary Fig. 36. The crystal structure was
validated with MolProbity48 and showed 98.1% of all residues in Ramachandran-
favoured and 100.0% in Ramachandran-allowed regions.
Protein ligand docking analysis. Protein Data Bank49 entry 3ZZA was used as
structure for the CVB3 3C protease. For a detailed binding conﬁrmation of
inhibitors 12 and 20 by ligand docking, see Supplementary Fig. 3. Docking was
performed using GOLD v 5.0.2 by the Cambridge Crystallographic Data Center
(Cambridge, UK, Europe) after protein preparation using MOE version 2,014.09
(ref. 50). The binding site was deﬁned using a radius of 10 Å around the sulfur
atom of cysteine 147. Docking was carried out using the PLP scoring function51
with 25 GA runs per ligand in the most accurate mode without water molecules
and default parameter settings. Covalent docking was performed by constraining
the sulfur atom in the ligand and cysteine 147 to share the same position
coordinates. Docking poses were analysed and prioritized for S1 pocket binding
and putative covalent bond formation using 3D pharmacophore models developed
in LigandScout version 4.0 (ref. 52) based on crystal structures of the CVB3 3C
protease (3ZZ6, 3ZZ7, 3ZZ8, 3ZZ9, 3ZZA, 3ZZB). Graphical representations of
selected conformations were generated using the PyMOL Molecular Graphics
System, Version 1.7.4 Schro¨dinger, LLC.
Data availability. Data supporting the ﬁndings of this study are available within
the article and its Supplementary Information ﬁles and from the corresponding
author upon reasonable request. The crystal structure presented within this article
is deposited under PDB code 5IYT.
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